Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | MAX | P61244 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | YAP1 | P46937 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30062650 | 1.00 | ABCG2 (0.48) | ABCG2MYCMAXAKR1C3AKR1C2 | |
| SCHEMBL25790940 | 0.93 | ABCG2 (0.41) | ABCG2MYCMAXAKR1C3AKR1C2 | |
| SCHEMBL21054627 | 0.89 | AKR1C3 (0.51) | ABCG2AKR1C3AKR1C2ABCB1MAPT | |
| SCHEMBL30062663 | 0.89 | AKR1C3 (0.51) | ABCG2AKR1C3AKR1C2ABCB1MAPT | |
| SCHEMBL21054301 | 0.89 | AKR1C3 (0.47) | ABCG2MYCMAXAKR1C3AKR1C2 | |
| SCHEMBL29438861 | 0.89 | AKR1C3 (0.47) | ABCG2MYCMAXAKR1C3AKR1C2 | |
| SCHEMBL25790954 | 0.89 | GAA (0.39) | ABCG2MYCMAXAKR1C3AKR1C2 | |
| SCHEMBL21054808 | 0.88 | AKR1C3 (0.45) | ABCG2AKR1C3AKR1C2ABCB1TEAD1 | |
| SCHEMBL30062661 | 0.88 | AKR1C3 (0.45) | ABCG2AKR1C3AKR1C2ABCB1TEAD1 | |
| SCHEMBL21054644 | 0.88 | ABCG2 (0.46) | ABCG2AKR1C3AKR1C2TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11524943-B1 | Benzocarbonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3720430-A1 | BENZOCARBONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019113236-A1 | BENZOCARBONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113236-A1 | BENZOCARBONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524943-B1 | Benzocarbonyl compounds | YAP1, TEAD2, TEAD3 | ABCG2 2776/4885MYC 6/4885MAX 2612/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | ABCG2 2217/4885MYC 31/4885MAX 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.